Patents by Inventor Jennifer Joy Kordich

Jennifer Joy Kordich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DR5 RECEPTOR AGONIST COMBINATIONS
    Publication number: 20190284290
    Abstract: The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of NK cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human DR5, or a cooperative combination of an anti-DR5 antibody and TRAIL. Administration of therapeutically effective amounts of an apoptotic composition induces apoptosis of apoptosis sensitive cancer cells.
    Type: Application
    Filed: October 31, 2018
    Publication date: September 19, 2019
    Inventors: Pamela Mary Holland, Jonathan David Graves, Jennifer Joy Kordich, Julia Catherine Piasecki, Ian Nevin Foltz
  • DR5 RECEPTOR AGONIST COMBINATIONS
    Publication number: 20150056204
    Abstract: The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of NK cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human DR5, or a cooperative combination of an anti-DR5 antibody and TRAIL. Administration of therapeutically effective amounts of an apoptotic composition induces apoptosis of apoptosis sensitive cancer cells.
    Type: Application
    Filed: March 27, 2013
    Publication date: February 26, 2015
    Inventors: Pamela Mary Holland, Jonathan David Graves, Jennifer Joy Kordich, Julia Catherine Piasecki, Ian Nevin Foltz
  • Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
    Patent number: 8735548
    Abstract: The present invention provides fusion proteins expressed by cancer cells, antibodies and other antigen-binding agents that specifically bind to the fusion proteins, and compositions and methods for using the antibodies and other antigen-binding agents to detect, characterize, and treat cancer.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: May 27, 2014
    Assignee: Amgen Inc.
    Inventors: Kim Coign Quon, Gene Cutler, Jennifer Joy Kordich
  • FUSION PROTEINS IN CANCER
    Publication number: 20130095111
    Abstract: The present invention provides fusion proteins expressed by cancer cells, antibodies and other antigen-binding agents that specifically bind to the fusion proteins, and compositions and methods for using the antibodies and other antigen-binding agents to detect, characterize, and treat cancer.
    Type: Application
    Filed: June 28, 2011
    Publication date: April 18, 2013
    Applicant: AMGEN INC.
    Inventors: Kim Coign Quon, Gene Cutler, Jennifer Joy Kordich
  • ENHANCED DEATH RECEPTOR AGONISTS
    Publication number: 20130064838
    Abstract: Methods and compositions for treatment of cancer in a human patient comprising administering a therapeutically effective amount of an Fc-polypeptide agonist of DR5 having high-affinity to FCGR3A. Methods of making the Fc-polypeptides are provided.
    Type: Application
    Filed: May 13, 2011
    Publication date: March 14, 2013
    Applicant: AMGEN INC.
    Inventors: Jonathan David Graves, Jennifer Joy Kordich, Susan Ellen Cottrell, Chang-Pin Huang
  • TREATMENT OF PANCREATIC CANCER USING A DR5 AGONIST IN COMBINATION WITH GEMCITABINE
    Publication number: 20120070432
    Abstract: Methods and compositions for treatment of exocrine pancreatic cancer in a human patient comprising administering a therapeutically effective amount of a DR5 agonist and gemcitabine. Methods and compositions for treating a patient by identifying the alleleic variant of Fc?RIIIA.
    Type: Application
    Filed: May 27, 2010
    Publication date: March 22, 2012
    Applicant: AMGEN INC.
    Inventors: Jeffrey Scott Wiezorek, Jonathan David Graves, Jennifer Joy Kordich